无乳链球菌
抗菌剂
微生物学
肺炎链球菌
红霉素
链球菌
苯甲酰胺
对接(动物)
抗菌活性
化学
体外
生物
细菌
抗生素
生物化学
立体化学
医学
遗传学
护理部
作者
Renata Perugini Biasi-Garbin,Marciéli Fábris,Ana Elisa Belotto Morguette,Gabriella Maria Andriani,Weslei Roberto Correia Cabral,Patrícia Morais Lopes Pereira,Tiago O. Brito,Fernando Macedo,Camilo Henrique da Silva Lima,César Armando Contreras Lancheros,Celso Vataru Nakamura,Phileno Pinge‐Filho,Eliandro Reis Tavares,Lucy Megumi Yamauchi,Marcelle de Lima Ferreira Bispo,Sueli Fumie Yamada‐Ogatta
标识
DOI:10.1002/slct.202202117
摘要
Abstract Herein, twenty‐six benzoylthioureas were evaluated for their antimicrobial activity against different bacterial and fungal species. Two 4‐substituted benzoylthiourea, one benzoylurea and one benzoylguanidine derivatives were further synthesized to identify the most promising compound. Eight compounds were active against at least one microbial species tested. N ‐(butylcarbamothioyl)‐benzamide ( 1 e ) exhibited the best antimicrobial activity towards Streptococcus agalactiae (group B Streptococcus ‐GBS), including clinical isolates susceptible or resistant to clindamycin and/or erythromycin and azithromycin. 1 e presented a bacteriostatic effect, causing morphological and ultrastructural alterations on planktonic cells, and decreased the metabolic activity of GBS biofilms. No hemolytic and cytotoxicity to mammalian cells were detected for 1 e , that also displayed drug‐likeness properties. Molecular docking was performed on Streptococcus pneumoniae enoyl‐ACP reductase obtained by homology modeling. 1 e showed relevant interactions with the GBS enoyl‐ACP reductase enzyme. N ‐(butylcarbamothioyl)‐benzamide may be a good starting point for the development of new antimicrobials against GBS.
科研通智能强力驱动
Strongly Powered by AbleSci AI